A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Number of Vaso-Occlusive Crises in Paediatric Patients Aged 6 Months to <18 Years with Sickle Cell Disease (HESTIA5)
Latest Information Update: 04 Sep 2020
At a glance
- Drugs Ticagrelor (Primary)
- Indications Sickle cell anaemia; Vaso-occlusive crisis
- Focus Registrational; Therapeutic Use
- Acronyms HESTIA 5
- Sponsors AstraZeneca; AstraZeneca AB
Most Recent Events
- 13 Jul 2020 Status changed from not yet recruiting to withdrawn prior to enrolment. as this study halted prematurely.
- 20 Feb 2020 New trial record